The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Biologics include a wide range of products , including: Vaccines. Definition of Biologic Products. Allergenics.

Development 180

Development Protein Production Hormones 180

XTalks

NOVEMBER 15, 2023

France-based biotech Valneva has won approval from the US Food and Drug Administration (FDA) for its chikungunya vaccine Ixchiq for the prevention of infection from the chikungunya virus. The vaccine is approved for adults 18 years of age and older who are at increased risk of exposure to the virus.

FDA Approval 59

FDA Approval Vaccination Vaccine In-Vitro 59

XTalks

MARCH 27, 2024

In vitro diagnostics, or IVD, is a field where precision, reliability and robust partnerships propel advancement. Each diagnostic evaluation and every lab discovery signify not only technological advancement but also the fruit of integrated teamwork, with decisions made collaboratively. Their significance in the field of IVD is paramount.

Manufacturing 108

Manufacturing Clinical Trials Clinical Trials In-Vitro 108

XTalks

SEPTEMBER 30, 2020

The researchers thought there may be similar mutations among COVID-19 patients, and that they could identify individuals at risk of developing severe disease as well as provide leads for new therapies, explained Casanova. Related: Low T Cell Counts Observed in COVID-19 Patients. Mutational Errors in COVID-19 Patients. percent of women and 12.5

Antibody 135

Antibody Genetics Research In-Vitro 135

The Pharma Data

SEPTEMBER 17, 2020

This is the focus of vaccines in development and convalescent plasma therapy. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. “As The test targets antibodies against the spike protein. Food and Drug Administration (FDA). said Thomas Schinecker, CEO Roche Diagnostics.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

pharmaphorum

AUGUST 4, 2022

Training and development. Staff development and training programmes were largely on pause during the pandemic. Businesses need to ensure they prioritise the recruitment and development of staff to help ensure longevity and survival. Harness technology.

Development 98

Development In-Vitro Manufacturing Compliance 98

pharmaphorum

JANUARY 22, 2021

So far, neither variant seems to be associated with more severe COVID-19 symptoms, although there has been some preliminary research suggesting the SA strain could allow reinfection with SARS-CoV-2, and also be less susceptible to vaccines. The UK strain – known as B.1.1.7

In-Vitro 141

In-Vitro RNA Licensing Licensing 141

The Pharma Data

MARCH 11, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

XTalks

JANUARY 15, 2021

Ortho Clinical Diagnostics received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its VITROS SARS-CoV-2 antigen test for detection of active COVID-19 infection. Related: COVID-19 Vaccine and Drug Development Coverage. active virus).

In-Vitro 105

In-Vitro Vaccination Vaccine Drugs 105

XTalks

DECEMBER 11, 2023

Through the utilization of their state-of-the-art technology and substantial investments in research and development (R&D), these med tech/medical device companies persist in driving industry innovation beyond the pandemic, thereby laying the foundation for a more streamlined approach against diseases in the future.

Production 110

Production Sales In-Vitro Development 110

Pharmaceutical Technology

SEPTEMBER 10, 2008

The first activities of the company concerned the pre-clinical toxicological testing of several new candidate molecules showing cytostatic activity, initially developed by a former research institute, as well as the breeding and supplying of laboratory animals. . It will most probably lead to a new anti-flu vaccine.

In-Vitro 100

In-Vitro Genotoxicity In-Vivo Development 100

Pharmaceutical Technology

JUNE 1, 2023

Pneumagen has raised £8m ($10 million) for the further development of its intranasal antiviral drug neumifil in Phase II studies for chronic obstructive pulmonary disease (COPD) patients suffering from virus-induced exacerbations. The vaccine is self-administered through an intranasal spray, and is based on the company’s GlycoTarge platform.

In-Vitro 130

In-Vitro Engineer Protein Vaccination 130

Delveinsight

JANUARY 6, 2021

As a result of the high healthcare cost, people from developed countries move from their home country to another to receive treatment. As a result of the high healthcare cost, people from developed countries move from their home country to another to receive treatment. What is Medical Tourism?

Cosmetics 79

Cosmetics In-Vitro Development Vaccination 79

Pharma Times

OCTOBER 1, 2022

Data further supports the continued development of FLU-v as a broad-spectrum influenza vaccine

In-Vitro 161

In-Vitro Vaccination Vaccine Development 161

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

Pharmaceutical Technology

MAY 26, 2023

Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. Research into genetic medicines like mRNA vaccines and gene therapies, as well as gene-editing treatments and novel cancer therapies, have driven increased demand for DNA.

DNA 130

DNA Manufacturing Gene Gene Therapy 130

XTalks

APRIL 27, 2022

In the US, the vaccination for the virus is currently provided to individuals five years of age and older. The in vitro studies showed that remdesivir was effective among the drugs because it had the strongest antiviral activity as it could block virus infection at low micromolar concentrations with minimal cell toxicity.

FDA Approval 98

FDA Approval In-Vitro Clinical Trials Clinical Trials 98

Pharmaceutical Technology

MAY 24, 2023

Our board and management team believe that the combined company will be well-positioned to develop powerful new therapies with the potential to overcome resistance to current immunotherapies, an area of significant unmet need.” Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0,

Gene Therapy 130

Gene Therapy In-Vivo In-Vitro Immune Response 130

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

Roots Analysis

OCTOBER 16, 2023

These clones can be manipulated and mutated in vitro to alter the expression and function of a protein. DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence.

DNA 40

DNA Gene Protein In-Vitro 40

Roots Analysis

OCTOBER 22, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.

RNA 40

RNA Protein Genetics Gene Expression 40

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

DECEMBER 20, 2020

Food and Drug Administration (FDA) is plenty busy with COVID-19 vaccine Emergency Use Authorizations (EUAs) this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. Athenex and Almirall have a license deal with Almirall having the license to research, develop and commercialize the drug in the U.S.

In-Vitro 52

In-Vitro FDA Approval Drugs Manufacturing 52

pharmaphorum

DECEMBER 16, 2020

We had companies collaborating to develop laboratories. Soon the ABPI and the entire industry were facing the ripple effects of COVID-19, including a significant slowdown in non-COVID clinical research, which Torbett says was challenging for the industry to deal with. “We’ve We had companies sourcing consumables for testing machines.

Vaccination 122

Vaccination Vaccine Life Science In-Vitro 122

The Pharma Data

JANUARY 16, 2021

It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibody drug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct. Etta Biotech is a leading cell electroporation technology and equipment supplier. JS Bio’s parent company.

Protein 52

Protein Production Antibody In-Vitro 52

The Pharma Data

OCTOBER 14, 2021

Therapeutic Area Head, Neurology Development at Sanofi. Therapeutic Area Head, Neurology Development at Sanofi. The results showed that after 48 weeks of treatment, tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by magnetic resonance imaging (MRI).

In-Vitro 52

In-Vitro Clinical Trials Clinical Trials Trials 52

The Pharma Data

DECEMBER 29, 2020

Program includes development of a heat-sensitive fluorescent SARS-CoV-2 detection assay through patient mucosal sampling. Due to the breadth of our antibody discovery capabilities, IPA is very well positioned to deliver anti-virus antibodies in various formats, opening doors for inclusion in different therapeutic and diagnostic approaches.

Antibody 52

Antibody In-Vitro Engineer Development 52

XTalks

AUGUST 12, 2020

The identification of T cells that essentially ‘hide’ the virus has significant implications for developing therapeutic strategies to improve the treatment and long-term management of HIV. This may help explain why HIV is adequately controlled, but not eradicated, with current treatments. The research study was published in Cell Reports.

RNA 52

RNA Protein DNA In-Vivo 52

The Pharma Data

DECEMBER 9, 2020

With the expected Emergency Use Authorization (EUA) of Pfizer – BioNTech and Moderna ’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience? Vigil Neuroscience. Led by industry veteran Ivana Magov?evi?-Liebisch

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

pharmaphorum

DECEMBER 15, 2022

Stefan Woxström is the new senior vice president for Europe and Canada at AstraZeneca, moving over from the company’s Japanese division to take over from Iskra Reic , who will now serve as EVP of vaccines and immune therapies. The month of November saw a number of notable hires and personnel moves in biotech and pharma. More CEO shakeups.

Sales 52

Sales In-Vitro Antibody Drug Delivery 52

The Pharma Data

FEBRUARY 25, 2022

“The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. Pfizer’s COVID-19 therapy Paxlovid, for example, targets Mpro.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

Roots Analysis

AUGUST 15, 2023

Overview of Cell Free Systems Cell-free systems are ­in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells. It is worth mentioning that the first reconstituted system, Protein Synthesis Using Recombinant Elements (PURE) , was developed in 2001.

Protein 52

Protein In-Vitro Reagent Production 52

The Pharma Data

JUNE 17, 2022

“The broadly neutralizing antibodies we described were more efficient in vitro than many anti–SARS-CoV-2 monoclonals previously approved by the FDA for treatment or prevention. A modified version of the Cv2.1169 antibody was also effective at treating SARS-CoV-2 infection in mice and hamsters.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

Roots Analysis

JANUARY 14, 2024

With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally.

Contract Manufacturing 40

Contract Manufacturing Protein Manufacturing Production 40

Delveinsight

FEBRUARY 23, 2021

The company develops transformative biologics including vaccines and therapeutics for the world’s most debilitating diseases. The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform.

In-Vitro 52

In-Vitro Vaccination Vaccine Licensing 52

World of DTC Marketing

JULY 12, 2021

SUMMARY: Pfizer says it has data on waning immunity from their COVID vaccine. According to a report on CNN.com “Pfizer said it is seeing waning immunity from its coronavirus vaccine and says it is picking up its efforts to develop a booster dose that will protect people from variants.” ” So who to believe?

Vaccination 292

Vaccination Vaccine In-Vitro Doctors 292